Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells
Open accessThe DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Abstract
The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Molecular pathways and cellular interactions involved in HSC activation and deactivation. Activated HSCs are the main effector cells during hepatic fibrosis. In the healthy liver, they metabolize and store retinoids. Upon activation by fibrogenic stimuli, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate α-smooth muscle actin (αSMA), and produce collagen I. Various factors, including immune cell-derived fibrogenic molecules, growth factors, and lipopolysaccharide, as well as profibrotic lipid mediators such as lysophosphatidylinositol and lysophosphatidic acid, induce HSC activation in the course of chronic liver disease. TGF-β is the most HSC potent activator, which is produced by infiltrating lymphocytes and monocytes, Kupffer cells (KCs), and damaged hepatocytes. IL-17, produced by neutrophils and Th17 cells, sensitizes HSCs to TGF-β by upregulating TGF-β receptor II (TGF-βRII). In addition, platelet-derived growth factor (PDGF), which is produced by endothelial cells and macrophages, further promotes HSC activation. During fibrosis resolution, HSCs either die or revert to an inactive state by upregulating transcription factors such as peroxisome proliferator-activated receptor-γ (PPARγ), GATA-binding factor 4 (GATA4), GATA6, and transcription factor 21 (TCF21). NK and CD8+ T cells can eliminate activated HSCs by inducing apoptosis (Further abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; HH, hedgehog ligands; IHH, Indian Hedgehog; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; LPS, lipopolysaccharide; miRNA, microRNA; MSR1, macrophage scavenger receptor 1; NF-κB, nuclear factor κ-light chain-enhancer of activated B cells; OPN, osteopontin; oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; SHH, sonic hedgehog; TLR4, Toll-like receptor 4). Modified from reference [5].](https://figures.cochat.ai/paper-figures/ba56d748dfcc4395a6907c0c93306af8/liver-fibrosis-from-basic-science-towards-clinical-progress-focusing-on-the-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A pivotal element in acute and chronic liver damage is hepatic stellate cells (HSCs) activation. In response to hepatocyte injury, HSCs transition into activated myofibroblasts, overproducing extracellular matrix components and driving fibrosis (Akkız H, 2024).”
From A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis (2026) · cites this paper as Akkız H, 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophil Extracellular Traps Kill Bacteria
Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., Weinrauch, Y., & Zychlinsky, A. (2004) · Science · doi:10.1126/science.1092385 · Cited by 10,268 · cited 2×
“Neutrophils are critical first responders of the innate immune system, and they can contribute to hepatic inflammation by producing proinflammatory cytokines and neutrophil extracellular traps (NETs), activating KCs, and recruiting additional types of immune cells [60–62].”
BackgroundMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 1×
“…factor, liver fibrosis reverts, going along with the decreased production of proinflammatory and profibrogenic cytokines, upregulated collagenolytic activity, the disappearance of fibrogenic cells, decreased ECM production, and, eventually, the dissolution of the fibrosis scar [1,2,4,5,13–17].”
BackgroundTGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380 · cited 3×
“Senescent HSCs are α -SMA-positive cells, but they neither proliferate nor produce collagen [2,5,10,11].”
BackgroundVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · cited 1×
“In contrast, successful antiviral treatment in patients with chronic viral hepatitis or with considerable lifestyle changes in NASH patients modulate the resolution of fibrosis [6–9].”
BackgroundInterleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372 · cited 1×
“ILCs, particularly ILC1s and ILC3s, are involved in liver fibrogenesis [82,83].”
BackgroundMolecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 10×
“…accumulation of bone marrow-derived inflammatory immune cells, secretion of proinflammatory cytokines, production of TGF-β by profibrogenic macrophages, activation of collagen type I (COLIAI)-secreting hepatic myofibroblasts, excessive production of the ECM, and the formation of a fibrous scar [4].”
BackgroundInfluentialAlcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963 · cited 1×
“In mice, the elimination of neutrophils or the deletion of neutrophil-derived soluble molecules (IL-8, IL-18, IL-17, CCL3, CCl 4 , and CCL2) attenuates the development of hepatic fibrosis [63,64].”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942 · cited 1×
“Blocking TLR4 signaling in mice or reducing hepatic exposure to intestinal microorganisms improves liver fibrosis [81].”
BackgroundFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 10×
“The combination of low extracellular pH with an increased lactic acid level promotes myofibroblast transformation through the activation of TGF-β 1 [1,144–146].”
BackgroundInfluential
Cited by
Items 101–197 of 197
Belyaev, G. P., Vyshtakalyuk, A. B., Парфенов, А. А., Galyametdinova, I. V., Semenov, V. E., & Васильевич, З. В. (2025) · Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učenye zapiski Kazanskogo gosudarstvennogo universiteta. Seriâ Estestvennye nauki · doi:10.26907/2542-064x.2025.2.276-296 · Cited by 1
Thijeel, K. S., Thuwaini, M. M., & Jasim, A. K. (2025) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2025.2.13
Du, X., Wang, M., Wang, Z., Xue, Z., Gao, Y., Ma, Y., Wang, Z., Liu, S., Ji, M., Yang, Y., et al. (2025) · Journal of Environmental Sciences · doi:10.1016/j.jes.2025.09.032
Zhang, J. G. (2025) · Research Square · doi:10.21203/rs.3.rs-6538340/v1
Zhang, L., Chen, H., Pang, X., Liu, T., Fan, C., Zhang, J., Furong, W., & Jiang, H. (2025) · DNA and Cell Biology · doi:10.1177/10445498251392182
Wei, J., Tan, Z., Wang, Z., Cheng, N., Ling, C., Pu, J., Cheng, L., & Wei, W. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.116439
Shiwan, Z., Guangcheng, L., & Mutalib, M. A. (2025) · Perinatal Journal · doi:10.57239/prn.25.033100100
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Current Research Status and Future Outlook of Non-Invasive Serum Biomarkers for Liver Fibrosis
郑, 瑞. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162536
Dastmalchi, N., Hajiasgharzadeh, K., Amooji, H., Alipour, M. R., Ahmadi, M., Mansoori, B., Nemati, H. H., & Khojasteh, S. M. B. (2025) · Biology Bulletin · doi:10.1134/s1062359025611334
“These cytokines, often released by activated Kupffer cells and infiltrating macrophages, facilitate HSC activation and promote fibrogenesis (Akkız et al., 2024).”
Akili, I. S., Miko, C., Saeed, A., Filosa, C., Orlowski, M., Sherman, A., Chan, A., Wan, M., Grenon, J., Thibeault, A., et al. (2026) · Experimental Physiology · doi:10.1113/ep093502 · Cited by 2
“This can result in sustained hepatocyte injury and systemic inflammation leading to more progressive liver disease, such as metabolic dysfunction associated steatotic liver disease (MASH) and fibrosis (Akkız et al., 2024).”
Arcoibe, R. N. (2025) · e_Buah
Molecular Perspective of GPNMB in the Progression of End-Stage Liver Disease
Aasarey, R., Prakash, S., Yadav, K., Priyatma, Khan, S., Medha, Vikram, N. K., Meena, S., Sharma, A., & Pandey, S. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01410-y
Tavaf, M. J., Abroun, S., Hashemi, M., Ghoytasi, I., Piryaei, A., Soleimani, M., Zarrabi, A., & Vosough, M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109748
Alotaibi, S. H., Samaha, M. M., Helal, M. G., & El‐Agamy, D. S. (2026) · Pharmaceuticals · doi:10.3390/ph19030504
“Excessive apoptosis contributes not only to hepatocyte loss but also to fibrosis, as apoptotic bodies stimulate HSC activation [36,37].”
Sun, J., Yang, R., Liu, M., Chen, Y., Zhang, Y., Gao, H., Ning, Z., Li, S., Saifullina, D., Tian, X., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.045
“HSC, the principal source of fibrillar collagen in fibrotic liver, undergoes a transition to a myofibroblastic state upon injury, governed by complex signaling and transcriptional reprogramming 13 .”
Zhu, X., Zhou, Y., Mingyu, R., Yang, X., Pei, G., & Tan, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-45925-z
“On the one hand, these pro-inflammatory macrophages secrete numerous cytokines that directly activate quiescent HSCs to facilitate excessive extracellular matrix deposition 29 .”
InfluentialEpigallocatechin Gallate as an Anti-Fibrotic Agent
Tarahovsky, Y. S., Gaidin, S. G., & Kim, Y. (2026) · Biochemistry (Moscow) · doi:10.1134/s0006297925603715
Precise delivery of medical gases by engineered nanomedicine for enhanced liver fibrosis therapy
Tian, P., Wang, J., Yang, H., Jiang, Z., Xu, J., Xu, X., Ni, N., Liu, T., & Sun, X. J. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103104
“The progression to advanced fibrosis and cirrhosis also results in significant vascular changes, formation of regeneration nodules, and portal hypertension [10,11].”
Egba, S. I., Orhonigbe, I. O., Achi, N. K., Ikechukwu, G. C., Chukwu, C. N., & Omeoga, H. C. (2026) · Biologics · doi:10.2147/btt.s603345
Advancing liver disease treatment: The promise of phytotherapy and hepatic stellate cell modulation
Chatterjee, N., & Mungamuri, S. K. (2025) · Journal of Clinical and Experimental Gastroenterology · doi:10.46439/gastro.4.026
Nadir, Y., Esselmani, H., Oukhdouch, A., Nechchadi, H., Ennadi, R., Lkousse, M. A., Farouk, I., Najimi, M., & Merzouki, M. (2026) · BioMedInformatics · doi:10.3390/biomedinformatics6030023
“Chronic liver damage and inflammation lead to hepatic fibrosis, promoting the activation of HSCs and their differentiation into myofibroblast-like cells [29,30].”
Unraveling inflammation's role in tumorigenesis: Toward rational anticancer therapeutic design
Chakraborty, S., Boyina, H. K., Sanka, K., Komakula, S. S. B., Pramoda, N. S., & Aligeti, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36500-3.00010-6
Wang, J., Huang, J., Zhang, M., Liu, X., Liu, Y., Zhang, Y., Wang, X., Zhou, H., Chen, D., Shen, Z., et al. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118737
The effects of Tissue-type Plasminogen Activator on PSC Activation
Zha, M., Wei, Y., & Zhang, S. (2026) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303394327251127145651
Recent advances in engineered exosomes for targeted microRNA delivery to reverse liver fibrosis
Miyanroodan, S. M., & Sohail, M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108447 · Cited by 1
(Păunescu), A. D., (Șuțan), N. A. I., Soare, L. C., Ponepal, C. M., Ţânţu, A. C., Ţânţu, M. M., Baniţă, I. M., & Pisoschi, C. G. (2026) · Diseases · doi:10.3390/diseases14050165
“GFAP expression also showed a strong positive correlation with fibrosis stage. suggesting that HSCs activation markers may persist during disease progression, reflecting ongoing cellular activation [28,63,64].”
Metabolic reprogramming and epigenetic memory of hepatic stellate cells in MASLD progression
Deng, Z.-Y., Huang, M.-L., & Liu, X.-Y. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i4.295
Adeyemi, D. O., & Ibitoye, A. O. (2026) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2025.12.012
Shang, F., Cui, X., Wang, B., Liu, F., & Tian, Q. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.115071
Liu, Z., & Liu, X. (2026) · medRxiv · doi:10.64898/2026.05.17.26353417
Learning ordinal representation across MRI sequences for liver fibrosis staging
Huo, J., Wang, Y., Wu, N., Zhang, R., Zhang, J., & Jin, W. (2026) · Medical Physics · doi:10.1002/mp.70504
Zhu, Z., An, J., Zhang, Z., Gao, F., Liao, D., Wang, J., Yin, H., Huang, X., Kang, K., Liu, Y., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04591-z
“Research has shown that the development of TH17 cell promotes pro-inflammatory responses in almost all tissues [11, 12].”
Lin, S., Lu, F., Li, Q., Zhang, K., Zhang, W., Chen, H., & Wang, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060682
PURPLE SWEET POTATO EXTRACT ATTENUATES GENTAMICIN-INDUCED HEPATOTOXICITY IN WISTAR RATS
Lusiana, E., Theodorus, & Putri, K. R. A. (2026) · International Archives of Medical Sciences and Public Health · doi:10.53806/iamsph.v7i1.1474
“Apoptotic hepatocytes may stimulate Kupffer cells and hepatic stellate cells (HSCs), thereby contributing to fibrogenic responses through secretion of TGF-β 1 , PDGF, and pro-inflammatory cytokines [18].”
Li, S., Wei, X., Han, X., Wang, J., Li, N., Liu, J., & Zhang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843391
Yu, J., (15202), L. W., Zhu, S.-L., Xiao, M., Huang, H.-X., Shao, Y., Bao, Q.-C., Ma, M.-M., & Chen, Y. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.06.006
Shan, X., Niu, Y., Ma, X., Wang, M., Li, Q., Wang, T., & Niu, D. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152940
Rahimi, S., Khoshnazar, S. M., Derakhshani, A., & Shahrokhi, N. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70207
“62 Serum cholesterol generally decreases in response to exosome-mediated activation of the PPAR γ /LXR α /ABCA1 pathway, especially in disease models characterized by lipid accumulation.”
Jung, J., Jin, M., Park, N., 최한이, & Na, K. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.06.032
PM2.5 as a driver of human health disorders: insights from the regulated cell death pathways
Khalilzad, M. A., Shoar, S. M. M., Abbasi, A., Falavarjani, M. S., Khalilzad, M., Naseri, A., & Najafi, S. (2026) · Military Medical Research · doi:10.1016/j.mmr.2026.100046 · Cited by 1
“Excess production and accumulation of ECM proteins, mainly collagen and fibronectin, are what cause liver fibrosis [178,179].”
Gorke, S., Sharma, S., Malik, A., & Abdullah, I. A. W. A. S. T. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015589
Guo, C., Yang, C., Zhang, J., Li, Y., & Wu, X. (2026) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2026.102706
Amatya, R., Min, K. A., & Shin, M. C. (2026) · Pharmaceuticals · doi:10.3390/ph19060962
“Kupffer cell-derived TNF-α and IL-1 β activate NF-κ B in quiescent HSCs, driving expression of Col1 α 1 (collagen type I) and α -SMA and promoting the survival of activated myofibroblastic HSCs [78,79].”
Hung, H., Minhalina, A. P., Hsu, P., Tsui, K.-H., Chao, T.-Y., & Liu, C. L. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119703
Meng, T., Jiang, Y., Guo, G., Dong, J., Lai, X., Liu, J., Rong, H., & Li, J. (2026) · Healthcare · doi:10.3390/healthcare14131986
Mocan, L. P., Mihu, C. M., Constantin, A.-M., Suflețel, R. T., Paunescu, I., Ilie, T., & Şovrea, A. S. (2026) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.67.1.04
“…upregulates collagen gene expression and amplifies TGF-β signaling in HSCs, while ROS generated during ethanol metabolism promotes lipid peroxidation and inflammatory signaling; sustained alcohol intake additionally impairs retinoid metabolism, reinforcing the myofibroblastic phenotype [62, 74].”
Shi, J., Zhou, X., Wu, J., Zeng, L., Wang, X., Li, W., Huang, X.-S., Deng, X., & Wang, W. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5920 · Cited by 1
“Upon activation, these cells trigger the excessive deposition of extracellular matrix (ECM) proteins such as collagen and fibronectin (FN), subsequently inducing hepatocyte apoptosis and cellular senescence and ultimately leading to LF development (22).”
Cerevisterol from Ophiocordyceps sinensis fruiting bodies against liver fibrosis
Yang, M., Sun, T., Han, R., Huichun, X., & Cao, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1825109
Dai, X., Gao, C., Zheng, S., Jin, N.-Y., Jia, S.-Y., Lian, L., Nan, J., Cui, Z., & Wu, Y. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158572
Jaba, S. A., Abdulsattar, S. A., & Al-Akayshee, R. J. (2026) · Baghdad Journal of Biochemistry and Applied Biological Sciences · doi:10.47419/bjbabs.v7i3.476
Tan, D., Qiao, M., Zhang, Q. X., Wang, C., Bai, X., Peng, F., & Wu, D. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070711 · Cited by 1
“It is characterized by hepatic stellate cell (HSC) activation and excessive extracellular matrix (ECM) accumulation and may progress to cirrhosis and hepatocellular carcinoma, thereby imposing a substantial global health burden [1].”
Sun, Y., Wu, H., Zhou, Y., Yin, P., Wu, L., Li, H., Zuo, S., Yang, Z. M., & Cao, K. (2026) · The FASEB Journal · doi:10.1096/fj.202504713r
“Upon pathological stimulation, HSCs become activated and transdifferentiate into proliferative, contractile myofibroblast-like cells, leading to ECM deposition [23–25].”
Adeyemi, D. O., & Ibitoye, A. O. (2026) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2026.06.005
Hao, L.-S., Xiao-shi, Y., Zhan, Z., Jiang, M., Ji, J., Xiu-jing, Z., Miao, X.-J., Wang, J. H., Yang, D., & Mao, J.-Q. (2026) · Current Medicinal Chemistry · doi:10.2174/0109298673453995260611223108
Xie, H., Wang, Y., Zhu, M., Hou, L., Sun, X., Gao, X., Gao, S., & Zhu, J. (2026) · Biological Procedures Online · doi:10.1186/s12575-026-00354-0
“HSCs are the main effector cells of liver fibrosis, and their activation is an important step in the progression of liver cirrhosis [29, 35].”
GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential
Gan, X., Zhang, L., Yu, T., Jin, S., Wu, Y., Xu, R., Zhang, Y., Zhang, J., Xu, L., & Wang, X. (2026) · Biomolecules · doi:10.3390/biom16071060
“Common triggers, including viral infections, exposure to chemical toxins, and inherited metabolic disorders, lead to the aberrant activation of hepatic stellate cells (HSCs) and other fibrogenic cell populations [2].”
Javed, F., Almutairi, N. H., Tariq, W., Noor, M., Javed, S., Haider, U., Shamlan, G. H., Abdi, G., & Aadil, R. M. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.72135
Li, S. X., Chang, Z., Liu, J. L., & Lu, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71294
Hu, Y., & Xiao, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168384
Eldin, A. S., El-Gayar, A. M., & Abdel‐Rahman, N. (2026) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2026.2707686
Lu, W., An, Z., Lu, M., Kong, J., Wang, L., Feng, X., & Wu, F. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl51017
Olivito, I., Basile, V., Graziani, A. P. M., Gharbi, N., & Macirella, R. (2026) · Journal of Xenobiotics · doi:10.3390/jox16040148
“Liver fibrosis is generally defined as the excessive accumulation of extracellular matrix proteins, including collagen, resulting from liver injury [33,40,57].”
Ren, Y., Hu, D., Li, L., Wang, L., & Meng, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911290
Epigenetic Regulation of Liver Fibrosis: Mechanisms and Therapeutic Implications
Tavaf, M. J., Varkiani, M. E., Abroun, S., Sarabi, P. A., Torabi, S., Rismani, E., Hammour, M. M., Nussler, A. K., & Vosough, M. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70064
Taimuri, Y., & Ahmad, R. (2026) · iLiver · doi:10.1016/j.iliver.2026.100260
戸田, 桂., Tamai, R., Tanaka, R., Araki, N., Ishihara, M., Kanji, H., Tsukayama, I., Kawakami, Y., Suzuki-Yamamoto, T., & Takahashi, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2026.159768
Context-dependent duality of senescent cells in liver fibrosis
Gu, Y., Zhan, L., Di, Y., Wu, H., Zhao, T., Zhang, F., & Wu, Q. (2026) · Liver Research · doi:10.1016/j.livres.2026.09.001
“36 Subsequently, activated HSCs undergo p53-dependent senescence.”
Yumei, Anda, Xue, R., HaSi, Bai, T., Bai, Y., & Han, Z. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.115169
Ling, H., Qiu, P., & Hu, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177920
“Chronically damaged hepatic microenvironments trigger an intricate cellular cascade wherein sustained innate immune (macrophage) activation stimulates hepatic stellate cells (HSCs) to transdifferentiate into extracellular matrix (ECM)-secreting myofibroblasts [5,6].”
Lu, X., & Li, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1912158
“The traditional view describes it as a linear transformation from the resting state to a myofibroblast-like phenotype (16).”
Special Issue “Liver Fibrosis: Molecular Pathogenesis, Diagnosis and Treatment”
Morales‐Ruiz, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177922
“Biasin et al. [Contribution 3] published a pilot study that tried to address this problem by combining rheology with Low-Field Nuclear Magnetic Resonance (LF-NMR).”
Dong, Z., Meng, C., Xu, F., Wang, P., Long, C., Ye, R., Qian, Y., Nagdy, M. M., Liao, Z., Meng, F., et al. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c03738
Rahman, M. A., Sim, D., Bhajan, S. K., Bishwas, A. K., Jalouli, M., Choi, J., Aktary, N., Park, S., Yoo, I., Rani, A., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1931181
“The persistent inflammatory reaction causes harm to hepatocytes, attracts immune cells, and results in liver fibrosis (Akkız et al., 2024).”
PXDN knockdown alleviates hepatic stellate cell activation by regulating GPX1
Ren, G., Zhou, W., Li, Y., Zhang, X., & Li, L. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168452
Ramos, J. M. O., VASCONCELLOS, J. G., do Nascimento, N. B., de Sousa, A. C., Giehl, M. L., Fischer, B. S., Ferreira, J. D. S., de Oliveira, J., Trindade, V. M. T., & Guma, F. T. C. R. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12715-9
Hawary, O. A., Wadie, W., El-Said, Y. A. M., & Hassan, O. F. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05903-8
Sun, X., Liang, Y., Zhang, T., Qi, W., Zheng, S., Li, S., Lu, X., Li, X., & Zao, X. (2026) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2026.100880
Li, Z., Kwan, X., Liu, Q., Chong, J., Jiang, X., Wang, J., 陈少东, & Liang, H. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48100988
Figueroa-Montes, L. E. (2025) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Lipotoxicity in MAFLD/MASH: cellular mechanisms and targetable nodes
Tawai, J., Zhou, K., & Xiong, J. (2026) · Targetome · doi:10.48130/targetome-0026-0047
Li, F., & Xi-dai, L. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i9.714
Hui, Y., & Liu, Q. (2026) · Toxics · doi:10.3390/toxics14100873
“Fibrosis may regress after removal of the underlying insult, although the extent and timing of recovery depend on injury severity, persistent inflammation, stellate-cell fate, and extracellular-matrix remodeling [2,4–6].”
Eid, A. M., EL-Gendy, A. O., & Ewees, M. G. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05961-y
Clinical significance of RNA modifications in hepatic fibrosis
薛玉芹, Ran, M., Wang, S., Dai, F., Bai, M., Wang, Y., 沈艾, Ye, J., Li, D., & Li, H. (2026) · iLiver · doi:10.1016/j.iliver.2026.100275
Yuan, M., Ye, J., Sun, X., Tong, Z., Wang, T., 谭仁香, & Wu, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179413
Yu, F., Yin, S., Jiayu, Z., & Sun, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1969017
“Activated macrophages directly promote HSC activation through secretion of cytokines such as TGF-β (123) and platelet-derived growth factor (PDGF) (124), forming an “inflam-mation–fibrosis” feedforward loop.”
Luo, S., He, Y., Cai, L., Liu, L., Zhang, Y., Si, L., 成秋宸, & Liang, Y. (2026) · Cytotechnology · doi:10.1007/s10616-026-01082-9
“In the absence of timely therapeutic intervention, liver fibrosis may progress to cirrhosis or hepatocellular carcinoma (HCC) (Akkız et al. 2024).”
Xu, W., Chen, L., Wu, Y., Chen, X., Yuan, M., Zheng, G., & Qiu, Z. (2026) · The EPMA Journal · doi:10.1007/s13167-026-00471-6
Szymonik, M., Krasucka, N., Krupa, M., Małek, D., Płaza-Kościańczuk, J., Kleinrok, J., Pająk, W., Rusztyn, K., Mazur, M., & Korolczuk, A. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100526
“HSCs, liver sinusoidal endothelial cells (LSECs) and hepatic macrophages form the liver microcirculatory microenvironment, which regulates vascular tone and controls inflammation [16].”
Tipping the Balance: Context and Cell-Specific Regulation of MMPs and TIMPs in Liver Fibrosis
Harris, S., Tyagi, P., & Huebert, R. C. (2026) · Biomolecules · doi:10.3390/biom16101513
“In response to acute or chronic hepatic injury, HSCs are activated by cytokines, chemokines, and growth factors secreted from damaged hepatocytes, cholangiocytes, liver sinusoidal endothelial cells, Kupffer cells, and other immune cells [53–55].”
Hu, Q., Zhang, H., Tian, S., Zhang, X., Shu, H., Xie, L., Yang, L., Wang, C., Li, C., Xu, L., et al. (2026) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2026.110524
Lu, W., Xu, J., Wang, K., Chen, Y., Cherubini, A., Valenti, L. V. C., Zheng, S., & Liu, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954491
Li, R., Huang, X., Li, S., & Zhang, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1916728
Targeting fibrosis: unraveling pathogenesis for therapeutic advances
Li, H., Xiong, J., Li, J., Yan, Q., Deng, X., Teng, X., Du, Q., Lai, M., Wang, C., Liu, B., et al. (2026) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbag033
Ma, Z., & Cong, M. (2026) · Hepatobiliary Communications · doi:10.1016/j.hbc.2026.100017
He, M.-K., Chen, Y., Chen, K., Huang, C.-T., Tang, C.-C., Yang, D.-J., Lee, C.-H., Hsu, C.-C., & Her, G. M. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168521
Metadata
- Authors
- Akkız, H., Gieseler, R. K., & Canbay, A.
- Affiliations
- Bahçeşehir University (TR)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Corresponding author
- Akkız, Hikmet
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-07-18
- Volume
- 25
- Issue
- 14
- Pages
- 7873
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11277292
- OpenAlex
- W4400775597
- Semantic Scholar
- 8810ad06f0650b984f245dec696c68e2f2723093
- Cited by
- 191
- References
- 223
- Citations by year
- 2026: 112 · 2025: 70 · 2024: 9
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cells, hepatic fibrogenesis, myofibroblast transdifferentiation, extracellular matrix deposition, hepatic stellate cell activation, HSC heterogeneity, macrophages, hepatocyte death, liver inflammation, antifibrotic therapy, cirrhosis reversal, cellular stress response, cytokines and chemokines
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Hepatic Stellate Cells, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.